Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/11/2022 | $5.00 → $4.00 | Buy | HC Wainwright & Co. |
| 8/25/2021 | $5.00 | Buy | HC Wainwright & Co. |
HC Wainwright & Co. reiterated coverage of Salarius Pharmaceuticals with a rating of Buy and set a new price target of $4.00 from $5.00 previously
HC Wainwright & Co. initiated coverage of Salarius Pharmaceuticals with a rating of Buy and set a new price target of $5.00
4 - Salarius Pharmaceuticals, Inc. (0001615219) (Issuer)
4 - Salarius Pharmaceuticals, Inc. (0001615219) (Issuer)
4 - Salarius Pharmaceuticals, Inc. (0001615219) (Issuer)
HOUSTON, July 14, 2025 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX) (Salarius or the Company) announces that on July 10, 2025 the Company received notification from The Nasdaq Stock Market LLC (Nasdaq) of an additional extension to regain compliance with Nasdaq Listing Rule 5550(b)(1) (Equity Standard) by late July 2025. As previously disclosed, Salarius must also regain compliance with Nasdaq Listing Rule 5550(a)(2) (Minimum Bid Price Requirement) by early August 2025. On April 23, 2025, Salarius was notified by Nasdaq that it was not in compliance with Nasdaq Listing Rule 5550(a)(2) because the closing bid price of Salarius' common stock for the prior 30 consecutive
Phase 1/2 clinical study evaluating seclidemstat in patients with MDS and CMML is progressing with updates expected later this year Company continues to advance its contemplated merger with Decoy Therapeutics HOUSTON, July 09, 2025 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX) (Salarius or the Company) announces that two animal studies recently published in peer-reviewed journals provide additional insight into the role of inhibiting lysine-demethylase 1 (LSD1 or KDM1A), a well-validated target in hematologic and solid tumors. Salarius' seclidemstat (SP-2577) is a first-in-class, orally bioavailable LSD1 inhibitor that is being evaluated in an investigator-initiated Ph
CAMBRIDGE, Mass. and HOUSTON, April 16, 2025 (GLOBE NEWSWIRE) -- Decoy Therapeutics, Inc. (Decoy), a privately held preclinical biopharmaceutical company engineering the next generation of peptide conjugate therapeutics, announces that Massachusetts Institute of Technology (MIT) Professor and Moderna co-founder Robert S. Langer, ScD will join the company's Scientific Advisory Board (SAB) upon the successful completion of Decoy's merger with Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX). As announced on January 13, 2025, Decoy and Salarius Pharmaceuticals signed a definitive agreement under which Decoy Therapeutics will merge with a wholly owned subsidiary of Salarius Pharmaceuticals, with t
CAMBRIDGE, Mass. and HOUSTON, April 16, 2025 (GLOBE NEWSWIRE) -- Decoy Therapeutics, Inc. (Decoy), a privately held preclinical biopharmaceutical company engineering the next generation of peptide conjugate therapeutics, announces that Massachusetts Institute of Technology (MIT) Professor and Moderna co-founder Robert S. Langer, ScD will join the company's Scientific Advisory Board (SAB) upon the successful completion of Decoy's merger with Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX). As announced on January 13, 2025, Decoy and Salarius Pharmaceuticals signed a definitive agreement under which Decoy Therapeutics will merge with a wholly owned subsidiary of Salarius Pharmaceuticals, with t
HOUSTON, Feb. 03, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with sarcomas, pediatric cancers, and other cancers, today announced that Daniela Santiesteban, Ph.D., has been named Director of the Company's new targeted protein degradation program. In this newly created position, Dr. Santiesteban will assume responsibility for overseeing the development of SP-3164, the program's lead drug candidate, and advancing it into clinical trials. Her appointment immediately follows Salarius' recent strategic expansion into the targeted protein degradation field through its acquisitio
8-K - Salarius Pharmaceuticals, Inc. (0001615219) (Filer)
8-K - Salarius Pharmaceuticals, Inc. (0001615219) (Filer)
8-K - Salarius Pharmaceuticals, Inc. (0001615219) (Filer)
HOUSTON, Dec. 08, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX), a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop cancer therapies for patients in need of new treatment options, will hold a conference call with slides to discuss recent clinical and preclinical data from its lead programs on December 14, 2022 at 11:00 a.m. Eastern time. Management will review recently announced interim results from its ongoing Phase 1/2 trial with seclidemstat in Ewing sarcoma and FET-rearranged sarcomas, as well as new clinical data from MD Anderson Cancer Center's study with seclidemstat plus azacytidine in hematological cancer
60% Confirmed Disease Control Rate1 and 7.4 Months Median Time to Tumor Progression for Ewing Sarcoma First-Relapse Patients No Disease Progression Observed in Either First- or Second-Relapse Ewing Sarcoma Patients Who Achieved Confirmed Disease Control HOUSTON, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX), a clinical-stage biopharmaceutical company using targeted protein inhibition and targeted protein degradation to develop therapies for patients with cancer in need of new treatment options, announces interim clinical trial results from the company's Phase 1/2 trial of its novel oral, reversible, targeted LSD1 inhibitor, seclidemstat, as a treatment fo
HOUSTON, Aug. 08, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX), a clinical-stage biopharmaceutical company developing cancer therapies for patients in need of new treatment options, today reported financial results for the three and six months ended June 30, 2022, and provided a business update. Highlights of the quarter and recent weeks included: Financial Highlights Cash and equivalents were $22.6 million as of June 30, 2022, compared with $29.2 million as of December 31, 2021Tightly managed expenses while progressing toward multiple near-term milestonesNet loss of $4.7 million, or $0.09 per share, compared with net loss of $3.1 million, or $0.07 per share,
SC 13G/A - Salarius Pharmaceuticals, Inc. (0001615219) (Subject)
SC 13G - Salarius Pharmaceuticals, Inc. (0001615219) (Subject)
SC 13G/A - Salarius Pharmaceuticals, Inc. (0001615219) (Subject)